QIAGEN's QCI Interpret software has been selected by the Danish National Genome Center, which is a significant partnership for the company. This will help Denmark implement whole-genome sequencing as the standard-of-care for relevant patient groups, advancing personalized medicine in the country. This partnership demonstrates QIAGEN's ability to support national precision medicine programs and is likely to have a positive short-term impact on the company's stock price.